Trevena's TRV027 Fails To Meet Primary, Secondary Endpoints In Phase 2

(RTTNews) - Trevena, Inc. (TRVN) Monday announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure. The company said it would focus on Phase 3 oliceridine pain program and its earlier stage programs.

David Soergel, chief medical officer said, "We are very disappointed that TRV027 failed to show the hoped for benefits to patients in the BLAST-AHF study."

BLAST-AHF was a randomized, double-blind, standard of care controlled trial in 618 patients with acute heart failure. The study compared TRV027 plus standard heart failure therapy versus placebo plus standard therapy.